[ad_1] 1 / 8 Biocon | Biotechnology firm said its unit Biocon Biologics announced the US market availability of YESINTEK (ustekinumab-kfce), a biosimilar to Stelara (ustekinumab). This makes YESINTEK one of the first biosimilar alternatives to enter the US market for the blockbuster immunology drug. YESINTEK is approved for the treatment of Crohn’s disease, ulcerative […]
Headline
Tag: Texmaco Rail and Engineering share price
Back To Top